- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02069041
A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer
Phase 1b Study of 5-FU/FA and Oxaliplatin (FOLFOX4) Plus Ramucirumab (LY3009806) in Patients With Advanced Hepatocellular Carcinoma
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
-
Tainan, Taiwan, 70403
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Taipei, Taiwan, 10048
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Taoyuan City, Taiwan, 33305
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Histological or cytological diagnosis of hepatocellular carcinoma (HCC) or imaging findings consistent with HCC in a participant with liver cirrhosis and alpha-fetoprotein > 200 nanogram per milliliter
- At least 1 measurable or non-measurable lesion
- Child-Pugh A
- Barcelona Clinic Liver Cancer (BCLC) stage C or BCLC stage B not amenable to locoregional therapy or refractory to locoregional therapy
- Eastern Cooperative Oncology Group Performance Status of 0 or 1
- Have not received previous systemic therapy for advanced HCC
- Have resolution to Grade ≤1 of all clinically significant toxic effects of prior locoregional therapy
- Adequate organ function including: Absolute neutrophil coun t≥1.5×109/liter (L), hemoglobin ≥9 gram/deciliter, and platelets ≥90×109/L; Total bilirubin level ≤1.5 the upper limit of the normal range (ULN), aspartate transaminase and alanine transaminase ≤5 ULN, albumin >28 gram/L; Serum creatinine level ≤1.5 ULN; or calculated serum creatinine clearance ≥50 milliliter/minute; International Normalized Ratio≤1.5 and partial thromboplastin time ≤5 seconds above ULN
- The urinary protein is ≤ 1+. If ≥ 2+ proteinuria, the 24-hour urine protein is <1000 milligram
- An estimated life expectancy of at least 12 weeks
Exclusion Criteria:
- Received any investigational therapy or non-approved drug within 28 days prior to enrollment
- Undergone major surgery within 28 days prior to enrollment, or undergone central venous access device placement within 7 days prior to enrollment
- Undergone hepatic locoregional therapy within 28 days prior to enrollment
- Undergone radiation to any nonhepatic site within 14 days prior to enrollment
- Prior liver transplant
- Fibrolamellar carcinoma or cholangiocellular carcinoma
- Received any transfusion, blood component preparation, erythropoietin, albumin preparation, or granulocyte-colony stimulating factors within 14 days prior to enrollment
- Receiving therapeutic anticoagulation with warfarin, low-molecular weight heparin, or similar agents
- Receiving ongoing therapy with nonsteroidal anti-inflammatory agents or other antiplatelet agents.
- Known human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness
- Active or uncontrolled clinically serious infection
- Uncontrolled thrombotic or hemorrhagic disorder
- Serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to enrollment
- History of gastrointestinal perforation or obstruction
- History of or current hepatic encephalopathy or current clinically meaningful ascites
- Known allergy to monoclonal antibody, fluorouracil, oxaliplatin or their excipients
- Interstitial pneumonia or interstitial fibrosis of the lung
- Central nervous system metastases or carcinomatous meningitis
- Known history of dihydropyrimidine dehydrogenase deficiency
- Symptomatic congestive heart failure, unstable angina pectoris, or symptomatic or poorly controlled cardiac arrhythmia
- Experienced any arterial thromboembolic event
- Uncontrolled arterial hypertension
- Grade 3-4 venous thromboembolic events occurring within 3 months prior to enrollment
- Experienced any grade 3-4 gastrointestinal bleeding or any variceal bleeding episode in the 3 months prior to enrollment requiring transfusion, endoscopic or operative intervention
- Esophageal or gastric varices that require immediate intervention or represent a high bleeding risk
- Pre-existing grade ≥ 2 motor or sensory neuropathy
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Ramucirumab + FOLFOX4
8 milligram/kilogram (mg/kg) ramucirumab given intravenously (IV) on Day 1 followed by FOLFOX4 (folinic acid + fluorouracil + oxaliplatin chemotherapy regimen) given IV on Day 1 of 2 week cycles: FOLFOX4 every 2 weeks: 85 milligram per square meter (mg/m²) oxaliplatin IV on Day 1 200 mg/m² folinic acid(FA) IV on days 1 and 2 400 mg/m² 5-FU bolus on days 1 and 2 600 mg/m2 5-FU 22-h continuous infusion on Days 1 and 2 Participants may continue to receive treatment until discontinuation criteria are met. |
Administreras IV.
Andra namn:
Administered IV.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Tidsram: Baseline through study completion (Up To 8 Months)
|
A summary of other non-serious Adverse Events (AEs), and all Serious Adverse Events (SAE's), regardless of causality, is located in the Reported Adverse Events section.
|
Baseline through study completion (Up To 8 Months)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ramucirumab
Tidsram: Cycle 1 and Cycle 3: 0,1.0,1.5,2.0,3.0,5.0,24.0,48.0,168.0,336.0 hours
|
Maximum Concentration (Cmax)
|
Cycle 1 and Cycle 3: 0,1.0,1.5,2.0,3.0,5.0,24.0,48.0,168.0,336.0 hours
|
PK:Area Under the Concentration-Time Curve (AUC[0-∞]) of Ramucirumab
Tidsram: Cycle 1 and Cycle 3: 0,1.0,1.5,2.0,3.0,5.0,24.0,48.0,168.0,336.0 hours
|
Area under the concentration-time curve.
|
Cycle 1 and Cycle 3: 0,1.0,1.5,2.0,3.0,5.0,24.0,48.0,168.0,336.0 hours
|
Number of Participants With Anti-Ramucirumab Antibodies
Tidsram: Baseline through 6.1 Months
|
Baseline through 6.1 Months
|
|
Percentage of Participants With Best Response of Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])
Tidsram: Response to Disease Progression or Death (Up To 7 Months)
|
Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version[v] 1.1) criteria.CR was defined as the disappearance of all target and non-target lesions and all target and non-target lymph nodes were non-pathological or normal in size [<10 millimeter (mm) short axis]. PR is at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. Progressive Disease(PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest).In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. Percentage of participants with CR or PR= (number of participants whose best overall response was CR or PR)/(number of participants treated)*100. |
Response to Disease Progression or Death (Up To 7 Months)
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Matsmältningssystemets sjukdomar
- Neoplasmer efter histologisk typ
- Neoplasmer
- Neoplasmer efter plats
- Adenocarcinom
- Neoplasmer, körtel och epitel
- Neoplasmer i matsmältningssystemet
- Leversjukdomar
- Neoplasmer i levern
- Carcinom
- Karcinom, hepatocellulärt
- Läkemedels fysiologiska effekter
- Molekylära mekanismer för farmakologisk verkan
- Antimetaboliter, antineoplastiska
- Antimetaboliter
- Antineoplastiska medel
- Immunsuppressiva medel
- Immunologiska faktorer
- Skyddsmedel
- Mikronäringsämnen
- Vitaminer
- Motgift
- Vitamin B-komplex
- Fluorouracil
- Oxaliplatin
- Leucovorin
- Ramucirumab
Andra studie-ID-nummer
- 15233
- I4T-CR-JVCQ (Annan identifierare: Eli Lilly and Company)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Karcinom, hepatocellulärt
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeOral Cavity Carcinom | Oral intraepitelial neoplasiFörenta staterna
-
Indira Gandhi Medical College, ShimlaOkänd
-
Endo PharmaceuticalsAvslutad
-
Fujian Provincial HospitalRekryteringCarcinom in situ i cervikal del av matstrupenKina
-
China Medical University, ChinaShanghai First Song Therapeutics Co., LtdRekrytering
-
Centre Georges Francois LeclercAvslutad
-
Genentech, Inc.Indragen
-
Ontario Clinical Oncology Group (OCOG)Avslutad
-
Ronald BuckanovichGenentech, Inc.RekryteringPARP-hämmare | Platinaresistent fallopian Tube Carcinom | Platinaresistent primärt peritonealt karcinom | Hedgehog InhibitorFörenta staterna
-
Washington University School of MedicineAvslutad
Kliniska prövningar på Ramucirumab
-
Shanghai Henlius BiotechAvslutad
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.AvslutadMagcancer | Icke-småcellig lungcancer | Kolorektal cancerKina
-
Yonsei UniversityHar inte rekryterat ännu
-
Eli Lilly and CompanyParexelAvslutad
-
Eli Lilly and CompanyAvslutad
-
Eli Lilly and CompanyAvslutadBröstcancerFörenta staterna
-
Yale UniversityIndragenÖvergångscellkarcinomFörenta staterna
-
Samsung Medical CenterRekrytering
-
Eli Lilly and CompanyAvslutadHepatocellulärt karcinomFörenta staterna, Kanada, Belgien, Tyskland, Israel, Korea, Republiken av, Spanien, Australien, Österrike, Brasilien, Frankrike, Italien, Japan, Portugal, Taiwan, Rumänien, Bulgarien, Tjeckien, Finland, Hong Kong, Ungern, Nederländ... och mer
-
Tianjin Medical University Cancer Institute and...RekryteringAvancerat hepatocellulärt karcinom som har misslyckats vid systemisk terapiKina